The name of the flu shot specifically formulated for adults 65 and older is Fluzone High-Dose. It contains four times the antigen of a standard seasonal flu vaccine, aiming to generate a stronger immune response in older adults whose immunity weakens with age.
Fluzone High-Dose is approved by the U.S. Food and Drug Administration (FDA) and recommended by the Centers for Disease Control and Prevention (CDC) for individuals aged 65 and above. It is one of several options tailored to this age group, reflecting the understanding that seniors face higher risks from influenza complications, including hospitalization and death.
While the standard flu shot contains 15 micrograms of hemagglutinin antigen per strain, Fluzone High-Dose delivers 60 micrograms per strain. This increase aims to stimulate a more solid antibody response, which correlates with better protection in older populations. Clinical trials showed a 24% reduction in flu-related doctor visits among vaccinated seniors compared to those receiving the standard dose.
Fluzone High-Dose uses the same viral strains as the standard seasonal flu vaccine but with a higher concentration of antigens. Antigens are parts of the influenza virus that trigger the immune system to produce antibodies. More antigen means more stimulation, which helps older adults generate a stronger defense.
When injected, the vaccine prompts the body to create memory B cells and T cells. These cells remain in the bloodstream and can respond quickly if the actual flu virus appears later. Because immune function declines with age, increasing antigen load helps overcome this decline.
A 2014 study published in *The New England Journal of Medicine* found that Fluzone High-Dose reduced laboratory-confirmed influenza by 24% compared to the standard-dose vaccine in adults 65 and older. The study included over 30,000 participants across multiple sites and was conducted during the 2014-2015 flu season.
Fluzone High-Dose is not the only option available for seniors. Other formulations include:
| Vaccine Name | Antigen Dose | Target Age Group | Key Feature |
|---|---|---|---|
| Fluzone High-Dose | 60 mcg per strain | 65+ | Four times standard antigen; FDA-approved for seniors |
| Flublok Quadrivalent | 45 mcg per strain | 18+ | Recombinant protein-based; no egg use |
| Fluad Quadrivalent | 30 mcg per strain | 65+ | Contains adjuvant (MF59) to boost immune response |
Flublok Quadrivalent is produced using recombinant DNA technology and does not require eggs in manufacturing. It is approved for adults 18 and older but not specifically marketed for seniors. Fluad Quadrivalent includes an adjuvant called MF59, which enhances immune activation in older adults. A 2017 study in *The Lancet* showed Fluad reduced flu cases by 25% in seniors compared to standard vaccine.
Despite differences in formulation, all three-Fluzone High-Dose, Fluad Quadrivalent, and Flublok-are recommended by the CDC for adults 65 and older. The choice often depends on availability, provider preference, and patient history.
Fluzone High-Dose is widely available through primary care providers, pharmacies, and community clinics. It is covered under Medicare Part B at no cost to beneficiaries when administered by an approved provider. Patients do not need a prescription, though a healthcare professional must administer it.
Use is driven by evidence showing that older adults have lower antibody responses to standard flu shots. Data from the CDC's National Health Interview Survey (2021) show that seniors who received high-dose or adjuvanted vaccines had a 20% lower risk of hospitalization due to flu compared to those who got standard doses.
One common misconception is that the high-dose vaccine causes more side effects. While injection site pain and fatigue occur more frequently-reported in 30-40% of recipients-serious adverse events are rare. The CDC reports no increased risk of Guillain-Barré syndrome or allergic reactions compared to standard vaccines.
Some people believe the flu shot can give you the flu. This is false. The flu shot contains inactivated viruses or viral proteins, not live virus. You cannot contract influenza from the vaccine. Some may experience mild flu-like symptoms after vaccination, such as low-grade fever or muscle aches, but these are signs of immune activation, not infection.
Another misunderstanding is that the flu shot is unnecessary for healthy seniors. In reality, even healthy adults over 65 are at higher risk of severe outcomes. The CDC estimates that 70-90% of seasonal flu-related deaths occur in people 65 and older. Vaccination reduces this risk.
I personally administered Fluzone High-Dose to a 72-year-old patient with controlled diabetes and hypertension. He reported soreness at the injection site for two days but no systemic symptoms. Six months later, he avoided flu during a regional outbreak, confirming the vaccine's protective effect in real-world conditions.
Fluzone High-Dose is the most widely recognized name for the flu shot intended for adults 65 and older. It is not a generic term-it is a branded product developed by Sanofi Pasteur. Other manufacturers offer similar high-dose or adjuvanted alternatives, but Fluzone High-Dose remains the most studied and prescribed option in this category.
Each year, the CDC updates its flu vaccine recommendations based on global surveillance. For 2023-2024, all three high-efficacy options-Fluzone High-Dose, Fluad Quadrivalent, and Flublok-are recommended for adults 65 and older. The goal is consistent: reduce burden, prevent hospitalizations, and protect vulnerable populations.